Published in

Wiley, Clinical and Experimental Dermatology, 5(34), p. 561-565, 2009

DOI: 10.1111/j.1365-2230.2009.03227.x

Links

Tools

Export citation

Search in Google Scholar

Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology.

Journal article published in 2009 by Chinoy H. Cooper R. G. Griffiths C. E. Madan, V. Madan, Chinoy H. Griffiths CEM Cooper R. Madan, H. Chinoy, C. E. M. Griffiths ORCID, R. G. Cooper, Bob Cooper
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

In the first part of this review we examined the evidence behind the association between idiopathic inflammatory myopathies (IIM) and cancers. In view of the well-recognised association between cancer and myositis (hence the term cancer-associated myositis, or CAM) clinicians responsible for the management of patients with myositis must make important decisions regarding how intensively they undertake searches for malignancy. Clinicians must also decide how often such searches are repeated, and again how intensively, so as to optimise both cancer detection and treatment, and thus patient survival. As the risks of CAM are greatest in dermatomyositis, this is an issue of obvious importance to dermatologists. In this second of the two part review we examine the role of autoantibodies as potential predictors of cancer risk in IIM.